Clinicians' Use of Breast Cancer Risk Assessment Tools According to Their Perceived Importance of Breast Cancer Risk Factors: an International Survey

Overview

Journal J Community Genet

Publisher Springer

Specialty Health Services

Date 2018 Mar 7

PMID 29508368

Citations 4

Authors

Anne Bredart

Jean-Luc Kop

Antonis C Antoniou

Alex P Cunningham

Antoine de Pauw

Marc Tischkowitz

Hans Ehrencrona

Marjanka K Schmidt

Sylvie Dolbeault

Kerstin Rhiem

Douglas F Easton

Peter Devilee

Dominique Stoppa-Lyonnet

Rita Schmutlzer

Affiliations

Soon will be listed here.

Abstract

The BOADICEA breast cancer (BC) risk assessment model and its associated Web Application v3 (BWA) tool are being extended to incorporate additional genetic and non-genetic BC risk factors. From an online survey through the BOADICEA website and UK, Dutch, French and Swedish national genetic societies, we explored the relationships between the usage frequencies of the BWA and six other common BC risk assessment tools and respondents' perceived importance of BC risk factors. Respondents (N = 443) varied in age, country and clinical seniority but comprised mainly genetics health professionals (82%) and BWA users (93%). Oncology professionals perceived reproductive, hormonal (exogenous) and lifestyle BC risk factors as more important in BC risk assessment compared to genetics professionals (p values < 0.05 to 0.0001). BWA was used more frequently by respondents who gave high weight to breast tumour pathology and low weight to personal BC history as BC risk factors. BWA use was positively related to the weight given to hormonal BC risk factors. The importance attributed to lifestyle and BMI BC risk factors was not associated with the use of BWA or any of the other tools. Next version of the BWA encompassing additional BC risk factors will facilitate more comprehensive BC risk assessment in genetics and oncology practice.

Citing Articles

Prediction of Breast Cancer using Machine Learning Approaches.

Rabiei R, Ayyoubzadeh S, Sohrabei S, Esmaeili M, Atashi A J Biomed Phys Eng. 2022; 12(3):297-308.

PMID: 35698545 PMC: 9175124. DOI: 10.31661/jbpe.v0i0.2109-1403.

Survey on Physicians' Knowledge and Training Needs in Genetic Counseling in Germany.

Dick J, Aue V, Wesselmann S, Bredart A, Dolbeault S, Devilee P Breast Care (Basel). 2021; 16(4):389-395.

PMID: 34602945 PMC: 8436720. DOI: 10.1159/000511136.

Leveraging Health Information Technology to Collect Family Cancer History: A Systematic Review and Meta-Analysis.

Li X, Kahn R, Wing N, Ni Zhou Z, Lackner A, Krinsky H JCO Clin Cancer Inform. 2021; 5:775-788.

PMID: 34328789 PMC: 8812651. DOI: 10.1200/CCI.21.00004.

Patterns and Determinants of Attitudes towards Genetic Risk of Cancer: Case Study in a Malaysian Public University.

Sim E, Ting S Biomed Res Int. 2018; 2018:4682431.

PMID: 30112391 PMC: 6077651. DOI: 10.1155/2018/4682431.

References

Frank T, Deffenbaugh A, Reid J, Hulick M, Ward B, Lingenfelter B . Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol. 2002; 20(6):1480-90. DOI: 10.1200/JCO.2002.20.6.1480. View

Tyrer J, Duffy S, Cuzick J . A breast cancer prediction model incorporating familial and personal risk factors. Stat Med. 2004; 23(7):1111-30. DOI: 10.1002/sim.1668. View

Evans D, Eccles D, Rahman N, Young K, Bulman M, Amir E . A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO. J Med Genet. 2004; 41(6):474-80. PMC: 1735807. DOI: 10.1136/jmg.2003.017996. View

Antoniou A, Pharoah P, Smith P, Easton D . The BOADICEA model of genetic susceptibility to breast and ovarian cancer. Br J Cancer. 2004; 91(8):1580-90. PMC: 2409934. DOI: 10.1038/sj.bjc.6602175. View

Evans D, Lalloo F, Wallace A, Rahman N . Update on the Manchester Scoring System for BRCA1 and BRCA2 testing. J Med Genet. 2005; 42(7):e39. PMC: 1736089. DOI: 10.1136/jmg.2005.031989. View

Evans D, Howell A . Breast cancer risk-assessment models. Breast Cancer Res. 2007; 9(5):213. PMC: 2242652. DOI: 10.1186/bcr1750. View

Parmigiani G, Chen S, Iversen Jr E, Friebel T, Finkelstein D, Anton-Culver H . Validity of models for predicting BRCA1 and BRCA2 mutations. Ann Intern Med. 2007; 147(7):441-50. PMC: 2423214. DOI: 10.7326/0003-4819-147-7-200710020-00002. View

Antoniou A, Hardy R, Walker L, Evans D, Shenton A, Eeles R . Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics. J Med Genet. 2008; 45(7):425-31. DOI: 10.1136/jmg.2007.056556. View

Edwards P, Roberts I, Clarke M, DiGuiseppi C, Wentz R, Kwan I . Methods to increase response to postal and electronic questionnaires. Cochrane Database Syst Rev. 2009; (3):MR000008. PMC: 8941848. DOI: 10.1002/14651858.MR000008.pub4. View

10.

Claus E, Risch N, Thompson W . Genetic analysis of breast cancer in the cancer and steroid hormone study. Am J Hum Genet. 1991; 48(2):232-42. PMC: 1683001. View

11.

Amir E, Freedman O, Seruga B, Evans D . Assessing women at high risk of breast cancer: a review of risk assessment models. J Natl Cancer Inst. 2010; 102(10):680-91. DOI: 10.1093/jnci/djq088. View

12.

Meads C, Ahmed I, Riley R . A systematic review of breast cancer incidence risk prediction models with meta-analysis of their performance. Breast Cancer Res Treat. 2011; 132(2):365-77. DOI: 10.1007/s10549-011-1818-2. View

13.

Cunningham A, Antoniou A, Easton D . Clinical software development for the Web: lessons learned from the BOADICEA project. BMC Med Inform Decis Mak. 2012; 12:30. PMC: 3507671. DOI: 10.1186/1472-6947-12-30. View

14.

Quante A, Whittemore A, Shriver T, Strauch K, Terry M . Breast cancer risk assessment across the risk continuum: genetic and nongenetic risk factors contributing to differential model performance. Breast Cancer Res. 2012; 14(6):R144. PMC: 4053132. DOI: 10.1186/bcr3352. View

15.

Albada A, Vernooij M, van Osch L, Pijpe A, van Dulmen S, Ausems M . Does and should breast cancer genetic counselling include lifestyle advice?. Fam Cancer. 2013; 13(1):35-44. DOI: 10.1007/s10689-013-9672-5. View

16.

MacInnis R, Bickerstaffe A, Apicella C, Dite G, Dowty J, Aujard K . Prospective validation of the breast cancer risk prediction model BOADICEA and a batch-mode version BOADICEACentre. Br J Cancer. 2013; 109(5):1296-301. PMC: 3778274. DOI: 10.1038/bjc.2013.382. View

17.

Lee A, Cunningham A, Kuchenbaecker K, Mavaddat N, Easton D, Antoniou A . BOADICEA breast cancer risk prediction model: updates to cancer incidences, tumour pathology and web interface. Br J Cancer. 2013; 110(2):535-45. PMC: 3899766. DOI: 10.1038/bjc.2013.730. View

18.

Couch F, Nathanson K, Offit K . Two decades after BRCA: setting paradigms in personalized cancer care and prevention. Science. 2014; 343(6178):1466-70. PMC: 4074902. DOI: 10.1126/science.1251827. View

19.

Cottrell E, Roddy E, Rathod T, Thomas E, Porcheret M, Foster N . Maximising response from GPs to questionnaire surveys: do length or incentives make a difference?. BMC Med Res Methodol. 2015; 15:3. PMC: 4293861. DOI: 10.1186/1471-2288-15-3. View

20.

Lecarpentier J, Nogues C, Mouret-Fourme E, Buecher B, Gauthier-Villars M, Stoppa-Lyonnet D . Breast Cancer Risk Associated with Estrogen Exposure and Truncating Mutation Location in BRCA1/2 Carriers. Cancer Epidemiol Biomarkers Prev. 2015; 24(4):698-707. DOI: 10.1158/1055-9965.EPI-14-0884. View